CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
LICENSE AGREEMENTLicense Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is executed as of July 17, 2017 (the “Execution Date”), by and between Sarepta Therapeutics, Inc., with offices at 215 First Street, Suite 415, Cambridge, MA 02142, USA and Sarepta International C.V., with offices at Fred. Roeskestraat 123, 1076 EE Amsterdam, The Netherlands (collectively, “Sarepta”) on the one hand, and BioMarin Leiden Holding BV and its subsidiaries, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, “BioMarin”), on the other hand. BioMarin and Sarepta may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
FIRST AMENDMENT TO PLEDGE AGREEMENTPledge Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO PLEDGE AGREEMENT (this “Agreement”) is dated as of July 18, 2017 by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (the “Pledgor”), the Lenders party hereto and MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“MidCap”), as administrative agent to the Credit Agreement and Pledge Agreement described below (in such capacity, “Agent”).
AMENDMENT NO. 1 to the LICENSE AND COLLABORATION AGREEMENT between SUMMIT (OXFORD) LIMITED and SAREPTA THERAPEUTICS, INC.License and Collaboration Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the License and Collaboration Agreement (“Amendment No. 1”) is made on June 13, 2017 (“Amendment No. 1 Execution Date”), with retroactive effect to April 3, 2017 (“Amendment No. 1 Effective Date”), by and between Summit (Oxford) Limited, a company organized and existing under the laws of England and Wales (“Summit”) and Sarepta Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Sarepta”).
PLEDGE AGREEMENTPledge Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PLEDGE AGREEMENT (this “Agreement”) is made as of July 18, 2017, by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (“Pledgor”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as agent (in such capacity, together with its successors and assigns, “Agent”), for itself and the other Lenders (as defined herein).
Settlement AGREEMENTSettlement Agreement • August 3rd, 2017 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SETTLEMENT AGREEMENT (“Agreement”) is executed as of July 17, 2017 (the “Execution Date”), by and between Sarepta Therapeutics, Inc., with offices at 215 First Street, Suite 415, Cambridge, MA 02142, USA and Sarepta International C.V., with offices at Fred. Roeskestraat 123, 1076 EE Amsterdam, The Netherlands (collectively, “Sarepta”), The University of Western Australia having its principal office at 35 Stirling Highway, Crawley, Australia 6009 (“UWA”) on the one hand, and BioMarin Leiden Holding BV and its subsidiaries, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, “BioMarin”), and Academisch Ziekenhuis Leiden (“AZL”), having its principal office at Albinusdreef 2, 2333 ZA Leiden, Netherlands on the other hand. BioMarin, AZL, Sarepta and UWA may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
